Phapros Tbk PT
IDX:PEHA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| ID |
|
Phapros Tbk PT
IDX:PEHA
|
247B IDR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
302.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.3B USD |
Loading...
|
Market Distribution
| Min | -220 730.8% |
| 30th Percentile | 0% |
| Median | 3.7% |
| 70th Percentile | 9.8% |
| Max | 190 521.4% |
Other Profitability Ratios
Phapros Tbk PT
Glance View
PT Phapros Tbk is a pharmaceutical company, which engages in the production and marketing of pharmaceutical products. The company is headquartered in Jakarta Selatan, Dki Jakarta and currently employs 1,485 full-time employees. The company went IPO on 2018-12-26. The firm's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, DEXTROFEN S SYRUP 60ml, Diafac XR, Diafac 500 mg 10 tablets, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, Pehavask 5 & 10, Spirolactone 25 & 100, Dios, anemone, Pladel, and others. The firm also operates calibration laboratory. The company offers medicines for cardiovascular & hematopoietic, gastrointestinal & hepatobiliary, hormone Genito, urinary endocrine & metabolic, vitamins & minerals nutrition, dermatology, local anesthesia, immune & allergy, and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Phapros Tbk PT is -24.5%, which is below its 3-year median of -12.2%.
Over the last 3 years, Phapros Tbk PT’s Net Margin has decreased from 1.5% to -24.5%. During this period, it reached a low of -38.3% on Dec 31, 2024 and a high of 2.4% on Dec 31, 2022.
